Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $76,860,407 | $93,713,543 | $77,271,579 | $66,751,664 |
| - Cash | $2,488,200 | $2,730,000 | $3,105,900 | $2,885,600 |
| + Debt | $2,704,400 | $2,702,900 | $2,701,400 | $2,699,700 |
| Enterprise Value | $77,076,607 | $93,686,443 | $76,867,079 | $66,565,764 |
| Revenue | $14,202,000 | $13,117,200 | $12,172,900 | $16,071,700 |
| % Growth | 8.3% | 7.8% | -24.3% | – |
| Gross Profit | $12,231,500 | $10,872,700 | $10,467,700 | $13,348,000 |
| % Margin | 86.1% | 82.9% | 86% | 83.1% |
| EBITDA | $5,318,000 | $4,693,300 | $5,259,600 | $9,669,300 |
| % Margin | 37.4% | 35.8% | 43.2% | 60.2% |
| Net Income | $4,412,600 | $3,953,600 | $4,338,400 | $8,075,300 |
| % Margin | 31.1% | 30.1% | 35.6% | 50.2% |
| EPS Diluted | 38.34 | 34.77 | 38.22 | 71.97 |
| % Growth | 10.3% | -9% | -46.9% | – |
| Operating Cash Flow | $4,420,500 | $4,594,000 | $5,014,900 | $7,081,300 |
| Capital Expenditures | -$755,900 | -$926,400 | -$590,100 | -$551,900 |
| Free Cash Flow | $3,664,600 | $3,667,600 | $4,424,800 | $6,529,400 |